These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 37752742)

  • 21. Tolvaptan reduces the risk of worsening renal function in patients with acute decompensated heart failure in high-risk population.
    Matsue Y; Suzuki M; Seya M; Iwatsuka R; Mizukami A; Nagahori W; Ohno M; Matsumura A; Hashimoto Y
    J Cardiol; 2013 Feb; 61(2):169-74. PubMed ID: 23159210
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of the early use of V2 receptor antagonists in elderly patients with decompensated heart failure.
    Matsukawa R; Kubota T; Okabe M; Yamamoto Y; Meno H
    Heart Vessels; 2018 Feb; 33(2):145-154. PubMed ID: 28815407
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The relationship between the time until commencement of tolvaptan and the length of hospital stay in heart failure patients.
    Kiuchi S; Hisatake S; Kabuki T; Oka T; Dobashi S; Fujii T; Ikeda T
    Heart Vessels; 2018 Apr; 33(4):367-373. PubMed ID: 29128961
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vasopressin V2 receptor antagonist tolvaptan is effective in heart failure patients with reduced left ventricular systolic function and low blood pressure.
    Suzuki S; Yoshihisa A; Yamaki T; Sugimoto K; Kunii H; Nakazato K; Abe Y; Saito T; Ohwada T; Suzuki H; Saitoh S; Kubota I; Takeishi Y;
    Int Heart J; 2015; 56(2):213-8. PubMed ID: 25740399
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical safety and efficacy of tolvaptan for acute phase therapy in patients with low-flow and normal-flow severe aortic stenosis.
    Mitsui M; Kataoka A; Nara Y; Nagura F; Kawashima H; Hioki H; Nakashima M; Watanabe Y; Yokoyama N; Kozuma K
    Heart Vessels; 2019 Oct; 34(10):1684-1691. PubMed ID: 30993439
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Early Commencement and Long-Term Continuation of Tolvaptan Treatment Attenuate Functional Impairment of Renal Vasopressin V2 Receptors and Improve Clinical Outcomes in Patients with Heart Failure.
    Noto T; Osanami A; Nagano N; Kokubu N; Kouzu H; Tanno M
    Int Heart J; 2023 Mar; 64(1):36-43. PubMed ID: 36725078
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical Effectiveness of Tolvaptan in Patients With Acute Heart Failure and Renal Dysfunction.
    Matsue Y; Suzuki M; Torii S; Yamaguchi S; Fukamizu S; Ono Y; Fujii H; Kitai T; Nishioka T; Sugi K; Onishi Y; Noda M; Kagiyama N; Satoh Y; Yoshida K; Goldsmith SR
    J Card Fail; 2016 Jun; 22(6):423-32. PubMed ID: 26915749
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of early ultrafiltration in patients with acute decompensated heart failure with volume overload: a prospective, randomized, controlled clinical trial.
    Hu J; Wan Q; Zhang Y; Zhou J; Li M; Jiang L; Yuan F
    BMC Cardiovasc Disord; 2020 Oct; 20(1):447. PubMed ID: 33054727
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tolvaptan vs. furosemide-based diuretic regimens in patients hospitalized for heart failure with hyponatremia (AQUA-AHF).
    Ng TMH; Grazette LP; Fong MW; Yoon AJ; Lou M; Kuo A; Upadhyay RY; Han EE; Mehra A; Elkayam U
    ESC Heart Fail; 2020 Aug; 7(4):1927-1934. PubMed ID: 32543020
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical characteristics of responders to treatment with tolvaptan in patients with acute decompensated heart failure: Importance of preserved kidney size.
    Toda H; Nakamura K; Nakahama M; Wada T; Watanabe A; Hashimoto K; Terasaka R; Tokioka K; Nishii N; Miyoshi T; Kohno K; Kawai Y; Miyaji K; Koide Y; Tachibana M; Yoshioka R; Ito H;
    J Cardiol; 2016 Feb; 67(2):177-83. PubMed ID: 26072263
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Temporal trends in tolvaptan use after revision of national heart failure guidelines in Japan.
    Yamazaki Y; Shiraishi Y; Kohsaka S; Nagatomo Y; Fukuda K; Kohno T; Yoshikawa T
    Sci Rep; 2021 Sep; 11(1):19360. PubMed ID: 34588492
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial.
    Konstam MA; Gheorghiade M; Burnett JC; Grinfeld L; Maggioni AP; Swedberg K; Udelson JE; Zannad F; Cook T; Ouyang J; Zimmer C; Orlandi C;
    JAMA; 2007 Mar; 297(12):1319-31. PubMed ID: 17384437
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical efficacy of tolvaptan in acute decompensated heart failure patients with severe aortic stenosis and atrial fibrillation: a sub-analysis from the LOHAS registry.
    Murakami T; Watanabe Y; Nakamura N; Natsumeda M; Ohno Y; Nakazawa G; Ikari Y; Kataoka A; Nishihata Y; Hayashida K; Yamamoto M; Tanaka J; Jujo K; Izumo M; Mizutani K; Kozuma K
    Heart Vessels; 2024 Aug; 39(8):687-695. PubMed ID: 38710808
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of Tolvaptan in patients with acute heart failure: a systematic review and meta-analysis.
    Wang C; Xiong B; Cai L
    BMC Cardiovasc Disord; 2017 Jun; 17(1):164. PubMed ID: 28633650
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Renoprotective effect of tolvaptan in patients with new-onset acute heart failure.
    Kin H; Matsumura K; Yamamoto Y; Fujii K; Otagaki M; Takahashi H; Park H; Yoshioka K; Yokoi M; Sugiura T; Shiojima I
    ESC Heart Fail; 2020 Aug; 7(4):1764-1770. PubMed ID: 32383323
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of tolvaptan in patients hospitalized for worsening chronic heart failure with severe hyponatremia: The initial experience at a single-center in Turkey.
    Sağ S; Aydın Kaderli A; Yıldız A; Gül BC; Özdemir B; Baran İ; Güllülü S; Aydınlar A; Çavuşoğlu Y
    Turk Kardiyol Dern Ars; 2017 Jul; 45(5):415-425. PubMed ID: 28694395
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of urine cyclic AMP relative to plasma arginine vasopressin on response to tolvaptan in patients with chronic kidney disease and heart failure.
    Kakeshita K; Koike T; Imamura T; Fujioka H; Yamazaki H; Kinugawa K
    Clin Exp Nephrol; 2023 May; 27(5):427-434. PubMed ID: 36752971
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of chronic kidney disease on the diuretic response of tolvaptan in acute decompensated heart failure.
    Ikeda S; Ohshima K; Miyazaki S; Kadota H; Shimizu H; Ogimoto A; Hamada M
    ESC Heart Fail; 2017 Nov; 4(4):614-622. PubMed ID: 29154417
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term administration of tolvaptan ameliorates annual decline in estimated glomerular filtration rate in outpatients with chronic heart failure.
    Nakao K; Horio T; Yoshimura R; Fujiwara R; Matsuoka Y; Yokouchi G; Nakamura H; Sakamoto Y; Fujimoto K; Izumiya Y; Yoshiyama M; Kasayuki N
    Heart Vessels; 2021 Aug; 36(8):1175-1182. PubMed ID: 33580283
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials.
    Gheorghiade M; Konstam MA; Burnett JC; Grinfeld L; Maggioni AP; Swedberg K; Udelson JE; Zannad F; Cook T; Ouyang J; Zimmer C; Orlandi C;
    JAMA; 2007 Mar; 297(12):1332-43. PubMed ID: 17384438
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.